| COMPOSITION | |
|---|---|
| CEFIXIME ANHYDROUS | 200MG |
| DICLOXACILIN | 500MG |
CEFIXIME ANHYDROUS & DICLOXACILIN
CEFVIB DX
| SPECIFICATION | |
|---|---|
| FORM | TABLET |
| PACKING | 10×10 |
| PACKING TYPE | ALU ALU |
| MRP | |
DESCRIPTION
CEFIXIME ANHYDROUS
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
Dicloxacillin
One of the penicillins which is resistant to penicillinase. [PubChem]
SIDE EFFECTS
CEFIXIME ANHYDROUS
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.
Dicloxacillin
Oral LD<sub>50</sub> in rat is 3579 mg/kg. Symptoms of overexposure include irritation, rash, labored breathing, hives, itching, wheezing, nausea, chills, and fever.
INDICATION
Cefixime
For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis , (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes , (3) pharyngitis and tonsillitis caused by S. pyogenes , (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).
Dicloxacillin
Used to treat infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.